Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
Alison Backen(Cancer Research UK), Juan W. Valle(Cancer Research UK Manchester Institute), Justin S. Waters(Maidstone Hospital), Daniel H. Palmer(University of Liverpool), Andre Lopes(Cancer Research UK), Caroline Dive(University of Manchester), Mairéad G. McNamara(Australian and New Zealand Intensive Care Society), David Cunningham(Royal Marsden NHS Foundation Trust), Pippa Corrie(University of Cambridge), Anthony Maraveyas(University of Hull), Harpreet Wasan(Hammersmith Hospital), Marian Duggan(Cancer Research UK), Alan Anthoney(St James's University Hospital), John Bridgewater(University College London Hospitals NHS Foundation Trust), Paul J. Ross(King's College Hospital NHS Foundation Trust), William P. Steward(University of Leicester), Sandy Beare(King's College London), Charlotte Rees(University of Southampton), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cited by 26
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k